Last edition
News about "Dr Umesh Shaligram"
Eveliqure and Serum Institute of India Partner to Develop Anti-Diarrhoeal Vaccines
Eveliqure and Serum Institute of India (SII) have partnered to develop anti-diarrhoeal vaccines, with Eveliqure set to receive an upfront payment, milestone-based earnings and royalties on net sales, while SII will lead development and global commercialisation.
Dr Umesh Shaligram | 23/03/2026 | By News Bureau
Serum Institute to Produce 100,000 Doses of Oxford Rift Valley Fever Vaccine
Serum Institute of India will produce up to 100,000 doses of an investigational Rift Valley fever vaccine developed by the University of Oxford, as the viral disease continues to affect parts of West Africa. The doses may be used for testing and future outbreak response, under an agreement supported by CEPI.
Dr Umesh Shaligram | 17/01/2026 | By News Bureau | 104
CEPI, SII and Oxford University Collaborate to Develop Nipah Virus Vaccine Reserve
CEPI, the Serum Institute of India, and the University of Oxford have partnered to produce ChAdOx1 NipahB vaccine doses for Phase II trials and an investigational reserve of up to 100,000 doses, ready for rapid deployment in case of a future Nipah outbreak.
Dr Umesh Shaligram | 30/10/2025 | By Dineshwori | 328
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy